New Releases from NCBI BookshelfIptacopan (Fabhalta): Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia: Reimbursement Recommendation [Internet].​Iptacopan (Fabhalta): Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Fabhalta be reimbursed by public drug plans for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia, if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top